patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_708733 | REC_0004101 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 7.7 | 59 | male | 0 | 6 | 5.8 | 1 | osimertinib 80 mg daily | 6.3 | true | MSS | 2026-03-15T05:35:57.859646+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_153329 | REC_0004102 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 4.7 | 60 | male | 0 | 0 | 5.1 | 5 | pembrolizumab 200 mg q3w | 9.9 | true | MSS | 2026-03-15T05:35:57.859879+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323221 | REC_0004103 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 10.1 | 60 | male | 0 | 17 | 6.4 | 6 | osimertinib 80 mg daily | 16.9 | false | MSS | 2026-03-15T05:35:57.860187+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931225 | REC_0004104 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 12.2 | 67 | male | 1 | 14 | 5.8 | 2 | osimertinib 80 mg daily | 30.3 | true | MSS | 2026-03-15T05:35:57.860446+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_507071 | REC_0004105 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 17 | 9.9 | 68 | female | 0 | 14 | 6.2 | 2 | osimertinib 80 mg daily | 14.4 | false | MSS | 2026-03-15T05:35:57.860690+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_631955 | REC_0004106 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 7.2 | 62 | female | 1 | 20 | 4.2 | 7 | alectinib 600 mg BID | 16.5 | true | MSS | 2026-03-15T05:35:57.860931+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_544806 | REC_0004107 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 11.2 | 73 | female | 3 | 22 | 6.2 | 7 | osimertinib 80 mg daily | 8.3 | true | MSI-H | 2026-03-15T05:35:57.861177+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_375316 | REC_0004108 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 14.8 | 61 | female | 0 | 6 | 3.7 | 1 | osimertinib 80 mg daily | 11.5 | true | MSI-H | 2026-03-15T05:35:57.861433+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_989254 | REC_0004109 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 18 | 15.8 | 61 | male | 1 | 17 | 6.4 | 0 | entrectinib 600 mg daily | 35.9 | true | MSS | 2026-03-15T05:35:57.861828+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_714506 | REC_0004110 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 12.1 | 68 | female | 1 | 5 | 3.9 | 7 | osimertinib 80 mg daily | 10.8 | false | MSS | 2026-03-15T05:35:57.862078+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_321324 | REC_0004111 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 13.9 | 64 | female | 1 | 25 | 6.6 | 6 | alectinib 600 mg BID | 18.1 | false | MSI-H | 2026-03-15T05:35:57.862321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_694131 | REC_0004112 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 12.8 | 62 | female | 0 | 17 | 4.1 | 5 | osimertinib 80 mg daily | 10.3 | true | MSI-H | 2026-03-15T05:35:57.862559+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_606548 | REC_0004113 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 9 | 67 | female | 1 | 10 | 5.5 | 4 | entrectinib 600 mg daily | 18.1 | true | MSS | 2026-03-15T05:35:57.862791+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_477973 | REC_0004114 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 10.5 | 66 | female | 1 | 4 | 5.6 | 6 | osimertinib 80 mg daily | 6.3 | true | MSS | 2026-03-15T05:35:57.863025+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_441453 | REC_0004115 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 15.2 | 85 | male | 0 | 12 | 5.6 | 2 | osimertinib 80 mg daily | 17.1 | false | MSI-H | 2026-03-15T05:35:57.863263+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_799942 | REC_0004116 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 11.3 | 70 | male | 2 | 6 | 7.7 | 1 | sotorasib 960 mg daily | 21.9 | true | MSI-H | 2026-03-15T05:35:57.863501+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_991319 | REC_0004117 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 6.3 | 68 | female | 1 | 35 | 4.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 12.2 | true | MSS | 2026-03-15T05:35:57.863732+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_433235 | REC_0004118 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 11.6 | 58 | female | 0 | 20 | 3.8 | 6 | osimertinib 80 mg daily | 8.3 | false | MSS | 2026-03-15T05:35:57.863974+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_302792 | REC_0004119 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 8.1 | 84 | male | 1 | 57 | 6.3 | 7 | pembrolizumab 200 mg q3w | 14.1 | false | MSS | 2026-03-15T05:35:57.864263+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_395448 | REC_0004120 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 14.8 | 74 | female | 2 | 5 | 5.8 | 3 | sotorasib 960 mg daily | 9.4 | true | MSI-H | 2026-03-15T05:35:57.864511+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_946911 | REC_0004121 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 5.2 | 64 | male | 0 | 14 | 4.9 | 4 | pembrolizumab 200 mg q3w | 10 | false | MSS | 2026-03-15T05:35:57.864746+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132987 | REC_0004122 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 10.3 | 54 | female | 0 | 15 | 4.2 | 7 | entrectinib 600 mg daily | 16.1 | false | MSI-H | 2026-03-15T05:35:57.865045+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_395051 | REC_0004123 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 15 | 4.9 | 85 | female | 2 | 15 | 7.5 | 6 | pembrolizumab 200 mg q3w | 10.8 | false | MSS | 2026-03-15T05:35:57.865283+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_869672 | REC_0004124 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 34 | 10.2 | 79 | female | 2 | 5 | 6.3 | 4 | sotorasib 960 mg daily | 9.2 | true | MSI-H | 2026-03-15T05:35:57.865526+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_313058 | REC_0004125 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 13.7 | 62 | male | 0 | 25 | 5.2 | 2 | sotorasib 960 mg daily | 11.9 | false | MSS | 2026-03-15T05:35:57.865773+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_860947 | REC_0004126 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 12.8 | 61 | female | 1 | 13 | 7.4 | 8 | pembrolizumab 200 mg q3w | 14.3 | true | MSI-H | 2026-03-15T05:35:57.866011+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_691179 | REC_0004127 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 8 | 70 | female | 3 | 44 | 5.3 | 3 | carboplatin + paclitaxel + pembrolizumab | 6.3 | false | MSS | 2026-03-15T05:35:57.866240+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_293530 | REC_0004128 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 14 | 9.2 | 59 | female | 1 | 17 | 7.9 | 4 | sotorasib 960 mg daily | 9.9 | true | MSS | 2026-03-15T05:35:57.866470+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_289726 | REC_0004129 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 10.2 | 68 | female | 0 | 15 | 4.7 | 6 | alectinib 600 mg BID | 10.5 | true | MSI-H | 2026-03-15T05:35:57.866703+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_447036 | REC_0004130 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 14.4 | 65 | female | 1 | 14 | 7.6 | 4 | entrectinib 600 mg daily | 18 | false | MSS | 2026-03-15T05:35:57.866941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_864050 | REC_0004131 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 8.4 | 61 | male | 1 | 28 | 7.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 18.2 | false | MSS | 2026-03-15T05:35:57.867175+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_518429 | REC_0004132 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 14.8 | 57 | male | 1 | 17 | 7.7 | 6 | alectinib 600 mg BID | 10.9 | false | MSI-H | 2026-03-15T05:35:57.867414+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_784659 | REC_0004133 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 4.3 | 62 | male | 0 | 64 | 3.4 | 3 | carboplatin + paclitaxel + pembrolizumab | 12.5 | false | MSS | 2026-03-15T05:35:57.867646+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_606635 | REC_0004134 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 15.2 | 76 | female | 3 | 13 | 4.5 | 2 | osimertinib 80 mg daily | 17.7 | false | MSI-H | 2026-03-15T05:35:57.867880+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_415290 | REC_0004135 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 14.3 | 72 | female | 1 | 19 | 6.5 | 5 | osimertinib 80 mg daily | 4.6 | false | MSI-H | 2026-03-15T05:35:57.868245+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_726023 | REC_0004136 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 7.2 | 68 | female | 0 | 13 | 6.2 | 1 | alectinib 600 mg BID | 21.8 | false | MSS | 2026-03-15T05:35:57.868494+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_608775 | REC_0004137 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 18.5 | 72 | male | 1 | 14 | 3.6 | 2 | sotorasib 960 mg daily | 15.5 | true | MSS | 2026-03-15T05:35:57.868741+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_447223 | REC_0004138 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 4.3 | 76 | female | 1 | 35 | 6.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 20.4 | false | MSS | 2026-03-15T05:35:57.868971+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_599834 | REC_0004139 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 5.4 | 71 | female | 1 | 25 | 7 | 5 | carboplatin + paclitaxel + pembrolizumab | 6.6 | true | MSS | 2026-03-15T05:35:57.869203+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_418128 | REC_0004140 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 7.9 | 65 | male | 1 | 47 | 4.3 | 7 | carboplatin + paclitaxel + pembrolizumab | 5.9 | true | MSS | 2026-03-15T05:35:57.869435+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_925817 | REC_0004141 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 16.1 | 82 | male | 2 | 7 | 3 | 11 | osimertinib 80 mg daily | 10.2 | false | MSI-H | 2026-03-15T05:35:57.869670+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_724422 | REC_0004142 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 4.7 | 68 | female | 1 | 1 | 5.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 14.9 | false | MSS | 2026-03-15T05:35:57.869899+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_736575 | REC_0004143 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 11.2 | 63 | female | 1 | 15 | 5.6 | 1 | osimertinib 80 mg daily | 24.6 | true | MSS | 2026-03-15T05:35:57.870136+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_858438 | REC_0004144 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 40 | 7.4 | 71 | female | 1 | 18 | 5.4 | 3 | alectinib 600 mg BID | 12.6 | false | MSS | 2026-03-15T05:35:57.870364+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_551606 | REC_0004145 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 30 | 14.3 | 85 | male | 0 | 20 | 5.3 | 4 | pembrolizumab 200 mg q3w | 19.4 | true | MSI-H | 2026-03-15T05:35:57.870600+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_449691 | REC_0004146 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 20 | 7.8 | 69 | female | 0 | 23 | 4.9 | 6 | pembrolizumab 200 mg q3w | 17.8 | true | MSS | 2026-03-15T05:35:57.870829+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_321560 | REC_0004147 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 13.3 | 77 | female | 1 | 18 | 6.6 | 7 | osimertinib 80 mg daily | 17.2 | false | MSS | 2026-03-15T05:35:57.871062+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_976160 | REC_0004148 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 9.1 | 83 | female | 2 | 0 | 7.2 | 3 | alectinib 600 mg BID | 12.8 | false | MSS | 2026-03-15T05:35:57.871354+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_378628 | REC_0004149 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 6.6 | 72 | female | 2 | 31 | 7 | 7 | carboplatin + paclitaxel + pembrolizumab | 8.7 | false | MSS | 2026-03-15T05:35:57.871588+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_268772 | REC_0004150 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 5.9 | 77 | female | 0 | 16 | 4.8 | 3 | alectinib 600 mg BID | 8.9 | false | MSS | 2026-03-15T05:35:57.871814+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_461132 | REC_0004151 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 16 | 10.7 | 75 | female | 2 | 7 | 5.1 | 5 | osimertinib 80 mg daily | 8.6 | false | MSS | 2026-03-15T05:35:57.872047+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_410438 | REC_0004152 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 12.3 | 65 | female | 1 | 11 | 6.2 | 1 | alectinib 600 mg BID | 11.3 | false | MSS | 2026-03-15T05:35:57.872332+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_607250 | REC_0004153 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 15.9 | 68 | female | 1 | 19 | 4.9 | 2 | entrectinib 600 mg daily | 17.7 | true | MSS | 2026-03-15T05:35:57.872572+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_780367 | REC_0004154 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 6.5 | 67 | female | 0 | 55 | 5.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 21.9 | false | MSS | 2026-03-15T05:35:57.872808+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_553678 | REC_0004155 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 11.2 | 68 | female | 1 | 14 | 3 | 2 | alectinib 600 mg BID | 21.2 | true | MSS | 2026-03-15T05:35:57.873044+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_798928 | REC_0004156 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 19.1 | 58 | male | 1 | 8 | 5.8 | 2 | entrectinib 600 mg daily | 18.6 | true | MSI-H | 2026-03-15T05:35:57.873278+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_705891 | REC_0004157 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 16.8 | 77 | female | 3 | 18 | 5.7 | 5 | sotorasib 960 mg daily | 5.4 | false | MSS | 2026-03-15T05:35:57.873517+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_137685 | REC_0004158 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6.4 | 71 | female | 2 | 56 | 6.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 7.9 | false | MSS | 2026-03-15T05:35:57.873749+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_333137 | REC_0004159 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 17 | 65 | male | 0 | 8 | 4.8 | 4 | sotorasib 960 mg daily | 11.9 | false | MSI-H | 2026-03-15T05:35:57.873986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748316 | REC_0004160 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 9.2 | 55 | male | 0 | 22 | 7.6 | 3 | osimertinib 80 mg daily | 13.8 | false | MSS | 2026-03-15T05:35:57.874215+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_611026 | REC_0004161 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 9.9 | 65 | female | 0 | 23 | 8 | 5 | osimertinib 80 mg daily | 13.2 | false | MSS | 2026-03-15T05:35:57.874511+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_994353 | REC_0004162 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 8.7 | 65 | male | 0 | 22 | 6.3 | 2 | osimertinib 80 mg daily | 18.2 | false | MSS | 2026-03-15T05:35:57.874748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_464642 | REC_0004163 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 7.5 | 64 | male | 0 | 14 | 6.4 | 2 | entrectinib 600 mg daily | 17.1 | false | MSS | 2026-03-15T05:35:57.874987+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_918254 | REC_0004164 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 24 | 14.5 | 69 | female | 0 | 9 | 5.2 | 0 | entrectinib 600 mg daily | 56.7 | true | MSI-H | 2026-03-15T05:35:57.875223+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_569137 | REC_0004165 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 7.2 | 69 | female | 0 | 22 | 5 | 4 | carboplatin + paclitaxel + pembrolizumab | 8.7 | false | MSS | 2026-03-15T05:35:57.875451+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862083 | REC_0004166 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 8.9 | 75 | male | 2 | 36 | 3.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.6 | true | MSS | 2026-03-15T05:35:57.875681+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_245125 | REC_0004167 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 8.3 | 75 | female | 3 | 61 | 6.6 | 7 | carboplatin + paclitaxel + pembrolizumab | 15.6 | true | MSS | 2026-03-15T05:35:57.875909+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_373280 | REC_0004168 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 37 | 4.8 | 68 | male | 0 | 12 | 4.3 | 5 | pembrolizumab 200 mg q3w | 13.5 | false | MSS | 2026-03-15T05:35:57.876223+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_676920 | REC_0004169 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 4.8 | 69 | female | 0 | 56 | 5.4 | 4 | carboplatin + paclitaxel + pembrolizumab | 17.7 | false | MSS | 2026-03-15T05:35:57.876457+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_168317 | REC_0004170 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 9.7 | 78 | male | 1 | 21 | 7 | 3 | osimertinib 80 mg daily | 12.4 | false | MSS | 2026-03-15T05:35:57.876692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_391233 | REC_0004171 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 18 | 2.7 | 79 | female | 1 | 10 | 4.3 | 0 | entrectinib 600 mg daily | 16.8 | true | MSS | 2026-03-15T05:35:57.876923+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_870255 | REC_0004172 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 8.4 | 60 | male | 0 | 9 | 5.8 | 2 | alectinib 600 mg BID | 19.2 | false | MSS | 2026-03-15T05:35:57.877158+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_340911 | REC_0004173 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 16.2 | 61 | female | 0 | 8 | 6.8 | 5 | alectinib 600 mg BID | 9.7 | true | MSS | 2026-03-15T05:35:57.877393+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_735744 | REC_0004174 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 9.6 | 61 | male | 1 | 25 | 6 | 7 | carboplatin + paclitaxel + pembrolizumab | 5.5 | true | MSS | 2026-03-15T05:35:57.877676+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_662601 | REC_0004175 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 7.5 | 69 | male | 0 | 22 | 7.1 | 5 | pembrolizumab 200 mg q3w | 11.4 | false | MSS | 2026-03-15T05:35:57.877912+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_963928 | REC_0004176 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 15.5 | 76 | female | 2 | 19 | 4.8 | 1 | sotorasib 960 mg daily | 15.2 | true | MSI-H | 2026-03-15T05:35:57.878145+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132395 | REC_0004177 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 32 | 10.8 | 74 | female | 2 | 25 | 6 | 2 | osimertinib 80 mg daily | 11.3 | false | MSS | 2026-03-15T05:35:57.878378+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_923669 | REC_0004178 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 20.2 | 69 | female | 0 | 13 | 5.2 | 1 | sotorasib 960 mg daily | 25 | false | MSS | 2026-03-15T05:35:57.878606+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_867569 | REC_0004179 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 15.6 | 54 | female | 0 | 36 | 6 | 7 | osimertinib 80 mg daily | 14.2 | true | MSS | 2026-03-15T05:35:57.878840+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356784 | REC_0004180 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 14 | 59 | female | 0 | 15 | 4.8 | 7 | osimertinib 80 mg daily | 10.9 | true | MSI-H | 2026-03-15T05:35:57.879076+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_511689 | REC_0004181 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 11.2 | 51 | male | 0 | 22 | 3.4 | 1 | alectinib 600 mg BID | 21.7 | false | MSI-H | 2026-03-15T05:35:57.879316+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_647480 | REC_0004182 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 3.7 | 59 | female | 0 | 19 | 3.7 | 5 | osimertinib 80 mg daily | 13.7 | true | MSS | 2026-03-15T05:35:57.879554+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_969316 | REC_0004183 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 7 | 70 | female | 3 | 14 | 4.3 | 7 | pembrolizumab 200 mg q3w | 10.4 | true | MSS | 2026-03-15T05:35:57.879795+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_699867 | REC_0004184 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 12.2 | 60 | female | 0 | 1 | 3.3 | 7 | osimertinib 80 mg daily | 10.7 | false | MSS | 2026-03-15T05:35:57.880036+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988261 | REC_0004185 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 9.4 | 65 | female | 1 | 11 | 4.2 | 5 | alectinib 600 mg BID | 8.8 | false | MSS | 2026-03-15T05:35:57.880338+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764319 | REC_0004186 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 12.7 | 65 | male | 0 | 4 | 5.7 | 5 | osimertinib 80 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:57.880600+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_278583 | REC_0004187 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 28 | 10.7 | 75 | female | 1 | 10 | 5.4 | 1 | pembrolizumab 200 mg q3w | 9.6 | false | MSI-H | 2026-03-15T05:35:57.880965+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_330184 | REC_0004188 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 11.9 | 64 | male | 0 | 15 | 5.2 | 6 | alectinib 600 mg BID | 8.4 | true | MSS | 2026-03-15T05:35:57.881259+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_235163 | REC_0004189 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 17 | 15.4 | 66 | female | 1 | 17 | 5.4 | 1 | entrectinib 600 mg daily | 20.1 | true | MSI-H | 2026-03-15T05:35:57.881530+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_151828 | REC_0004190 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 9 | 72 | female | 1 | 9 | 5.7 | 6 | osimertinib 80 mg daily | 13.4 | true | MSS | 2026-03-15T05:35:57.881775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_770101 | REC_0004191 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 14.9 | 65 | male | 1 | 11 | 5.7 | 1 | alectinib 600 mg BID | 19.9 | true | MSS | 2026-03-15T05:35:57.882020+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_777068 | REC_0004192 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 9.4 | 68 | female | 0 | 11 | 4.5 | 6 | entrectinib 600 mg daily | 4.2 | false | MSS | 2026-03-15T05:35:57.882255+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_678129 | REC_0004193 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 14 | 6.9 | 57 | male | 1 | 16 | 4.7 | 2 | entrectinib 600 mg daily | 15.9 | true | MSS | 2026-03-15T05:35:57.882490+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_408484 | REC_0004194 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 17.2 | 61 | male | 0 | 18 | 7.3 | 8 | alectinib 600 mg BID | 5.5 | true | MSS | 2026-03-15T05:35:57.882723+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_972998 | REC_0004195 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 16.1 | 71 | female | 2 | 9 | 6.5 | 2 | sotorasib 960 mg daily | 22.2 | false | MSS | 2026-03-15T05:35:57.882959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344944 | REC_0004196 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 5.5 | 68 | female | 1 | 11 | 6.7 | 1 | pembrolizumab 200 mg q3w | 22.5 | false | MSS | 2026-03-15T05:35:57.883193+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_241461 | REC_0004197 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 18 | 14.5 | 65 | male | 1 | 17 | 5.7 | 5 | pembrolizumab 200 mg q3w | 11.7 | false | MSS | 2026-03-15T05:35:57.883431+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_854118 | REC_0004198 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 10.8 | 60 | male | 0 | 18 | 6.9 | 4 | osimertinib 80 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:57.883667+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_597766 | REC_0004199 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 23 | 10.2 | 73 | female | 1 | 25 | 7.4 | 0 | osimertinib 80 mg daily | 41 | true | MSI-H | 2026-03-15T05:35:57.883900+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_345759 | REC_0004200 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 10.9 | 76 | female | 2 | 14 | 3.7 | 2 | alectinib 600 mg BID | 20.1 | false | MSI-H | 2026-03-15T05:35:57.884301+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.